<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125290</url>
  </required_header>
  <id_info>
    <org_study_id>IPH4401-401</org_study_id>
    <nct_id>NCT04125290</nct_id>
  </id_info>
  <brief_title>US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)</brief_title>
  <acronym>PROXY</acronym>
  <official_title>US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to satisfy a post-marketing requirement (PMR) to provide
      evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65
      years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who
      have moderate renal impairment defined as an estimated GFR of 30-59 ml/min.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pivotal Phase 3 study (Study 1053) supported full approval of moxetumomab pasudotox-tdfk
      from the US Food and Drug Administration (FDA) for the treatment of adult patients with
      relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic
      therapies, including treatment with a PNA, on 13 September 2018. Since HCL is a rare disease,
      clinical research has limited information concerning the safety of moxetumomab pasudotox-tdfk
      in elderly patient populations and patients with moderate renal impairment.This study is
      being conducted to satisfy a post-marketing requirement (PMR) to provide evidence
      characterizing the safety of moxetumomab in these patients .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incident proportion of capillary leak syndrome</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of hemolytic uremic syndrome</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of renal toxicity</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of infusion related reactions</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of electrolyte and biochemical abnormalities</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
    <description>Electrolyte and biochemical abnormalities are defined as laboratory measurements of interest that exceed local laboratory standards</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of other medical events related to moxetumomab pasudotox-tdfk interruption or discontinuation</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident proportion of other serious medical events that are life-threatening, resulting in hospitalizations and/or death</measure>
    <time_frame>From day 1 of moxetumomab pasudotox-tdfk initiation up to 30 days after last dose of moxetumomab pasudotox-tdfk.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hairy Cell Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be patients who are prescribed moxetumomab-pasudotox-tdfk who are
        ≥65 years old at the time of starting initial treatment with moxetumomab pasudotox-tdfk or
        are ≥18 years old with moderate renal impairment defined as an estimated GFR of 30-59
        ml/min, at the time of starting initial treatment with moxetumomab pasudotox-tdfk. These
        two populations may not be mutually exclusive.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent, if required

          -  Patient received at least 1 dose of moxetumomab pasudotox-tdfk and has completed or
             discontinued the treatment

          -  Patient has a medical record available from the start of first dose of moxetumomab
             pasudotox tdfk

        AND at least 1 of the following:

          -  Patient is ≥65 years old at the time of starting initial treatment with moxetumomab
             pasudotox-tdfk OR

          -  Adult (≥18 years old) patient has moderate renal impairment, at the time of starting
             initial treatment with moxetumomab pasudotox-tdfk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Mitry, MD</last_name>
    <role>Study Director</role>
    <affiliation>Innate Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Innate Pharma Mitry Emmanuel, MD</last_name>
    <phone>+33430303197</phone>
    <email>emmanuel.mitry@innate-pharma.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucile Beautier</last_name>
    <phone>+33430303197</phone>
    <email>lucile.beautier@innate-pharma.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bouroncle BA. Thirty-five years in the progress of hairy cell leukemia. Leuk Lymphoma. 1994;14 Suppl 1:1-12. Review.</citation>
    <PMID>7820038</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.</citation>
    <PMID>30030507</PMID>
  </reference>
  <reference>
    <citation>Kreitman RJ, Cheson BD. Malignancy: Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. Hematology. 1999;4(4):283-303.</citation>
    <PMID>11399570</PMID>
  </reference>
  <reference>
    <citation>Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia. 1997 Jan;11(1):170.</citation>
    <PMID>9001435</PMID>
  </reference>
  <reference>
    <citation>Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10;27(2):250-5. doi: 10.1200/JCO.2007.15.1530. Epub 2008 Dec 8.</citation>
    <PMID>19064987</PMID>
  </reference>
  <reference>
    <citation>Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994 May 15;83(10):2906-11.</citation>
    <PMID>7910051</PMID>
  </reference>
  <reference>
    <citation>Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia. 1997 Jan;11(1):42-7.</citation>
    <PMID>9001417</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>capillary leak syndrome</keyword>
  <keyword>hemolytic uremic syndrome</keyword>
  <keyword>renal toxicity</keyword>
  <keyword>infusion-related reaction</keyword>
  <keyword>electrolyte abnormalities</keyword>
  <keyword>HCL and all relevant indications where LUMOXITI will be prescribed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

